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Abstract 
Malignant fibrous histiocytoma (MFH) is the most common fibroblastic tumor, but its 
cutaneous metastasis, especially in-transit metastasis, is extremely rare. We describe the 
case of a 30-year-old Japanese man with a recurrent MFH on the scalp accompanied by 
in-transit metastasis, which had been treated as a benign skin tumor 8 years before. The 
main bulk of the recurrent tumor was located in the dermis, but the metastatic tumor 
was mainly located in the subcutis. Generally, atypical fibroxanthoma, also known as 
cutaneous MFH, is rarely metastasized and presents a benign clinical course. Since there 
is a great difference between the prognosis of MFH and atypical fibroxanthoma, precise 
diagnosis of the primary tumor is essential. 
 
Introduction 
Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma of late 
adult life, and it is rare in young patients. It usually involves the deep soft tissues and the 
striated muscles of the proximal part of the extremities, particularly the lower extremities. 
Up to 25% of cases may arise in subcutaneous tissues, although less than 10% are confined 
to the subcutis without underlying fascial involvement [1]. The superficial form of 
cutaneous MFH is known as atypical fibroxanthoma (AFX). Although AFX is 
histologically indistinguishable from MFH, AFX invariably shows a more favorable 
prognosis that results from its superficial location [1]. More recently, O13 (CD99) was 
found to display immunoreactivity in cases of AFX, but it was negative for MFH [2]. 
CD99, also known as p30/32 glycoprotein or MIC-2 protein, is a cell surface protein 
encoded by genes on the X and Y chromosomes. It has been shown to be reactive in Case Rep Dermatol 2011;3:164–169 
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Ewing’s sarcoma, primitive neuroectodermal tumors, some lymphomas, and other 
mesenchymal tumors [3]. It is also reported that CD99 expression may be associated with 
the biologic behavior of some tumors because of its roles in T cell apoptosis [3]. 
Metastasis of MFH occurs most in the lung (90%), followed by bone (8%) and liver 
(1%). Concerning skin metastasis, only 8 cases of MFH with cutaneous metastasis were 
previously reported [4], and no cases of in-transit metastasis of MFH have been reported 
in the English literature so far. Here, we describe a case of MFH with in-transit metastasis. 
Similar to previous reports [5], this case suggests the importance of an accurate diagnosis 
for the prediction of prognosis. 
Case Report 
A 30-year-old man in good health presented to our department with a 3-year history of an 
asymptomatic, enlarging tumor on his scalp. The tumor was excised by a private physician 8 years 
before, but had recurred. Physical examination revealed a skin-colored, elastic hard, well-demarcated 
tumor on the left side of his occipital region (fig. 1). The tumor size was 40 mm in diameter. Moreover, 
there was an elastic hard, satellite nodule located 4 cm from the tumor. Biopsy specimens taken from 
the tumor revealed a significant number of minimal atypical spindle or stellate cells in the middle to 
deep dermis (fig. 2a). Immunohistochemistry showed that a significant number of factor XIIIa-positive 
cells was disseminated in the tumors (fig. 2b), and CD34-positive cells were limited (fig. 2c). The 
findings of the laboratory evaluation, including complete blood count, liver function tests and 
urinalysis, were all within normal limits. We excised the tumor with a 5-mm surgical margin and below 
the muscle fascia. Histopathology revealed that the main bulk of the tumor was located from the dermis 
to the subcutaneous tissue (fig. 3a). The dermal lesion consisted of minimal atypical spindle or stellate 
cells and foam cells within myxoid matrices (fig. 3b, c). Moreover, CD99 was limited in both the 
primary and metastatic tumor (fig. 3d). On the other hand, the satellite nodule was composed of densely 
proliferating spindle cells with moderate pleomorphism arranged in a haphazard fashion (fig. 3e), and, 
in contrast to the primary tumor, the satellite lesion was located in the subcutaneous tissue (fig. 3f). 
Immunohistochemically, both the primary tumor and the satellite nodule were positive for vimentin 
and CD31+, and negative for SMA, S100, desmin, HMB-45, Melan-A, AE1/AE3, and Cam5.2. From 
these results, we made the diagnosis of MFH with in-transit metastasis in our patient. We examined for 
possible distal metastasis by computed tomography scan, and detected no metastasis. Five years after the 
surgical treatment, there was no evidence of local recurrence or metastasis. 
Discussion 
We present a case of MFH with in-transit metastasis. In the present case, the primary 
tumor was mainly located in the dermis, similar to the cutaneous form of MFH, also 
known as AFX. As the metastasis of MFH occurs mainly through tumor vessels, in-transit 
metastasis of MFH is extremely rare. 
It is difficult to ascertain the biological behavior of MFH in the skin. In general, the 
prognosis of MFH is suggested to depend on the size of the initial lesion, as well as the 
depth of the tumor and the histological grade. Superficial tumors of less than 5 cm in 
diameter have an excellent prognosis. On the other hand, high-grade lesions situated deep 
in the skeletal muscle and measuring more than 10 cm in size are at great risk of 
metastasis [6]. In our case, the primary tumor was mainly confined to the dermis, had not 
penetrated into the muscle fascia and was less than 5 cm in diameter; however, local 
recurrence with in-transit metastasis occurred 8 years after the primary resection of the 
tumor. Because recurrence is frequently due to misdiagnosis of the proliferation as Case Rep Dermatol 2011;3:164–169 
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benign, our case strongly suggests the importance of a precise diagnosis and a complete 
resection of the primary tumor in the initial phase.  
Recently, Hartel et al. [2] reported a higher proportion of CD99 positivity in AFX 
compared with MFH (94 vs. 15%) and that the degree of CD99 expression is in part 
related to their different biologic behaviors. Since CD99 has been shown to play a role in 
T cell apoptosis [3], they concluded that the strong CD99 expression in AFX may be 
pathogenetically associated to some degree with a more effective apoptosis of tumor cells 
and, therefore, correlate with a benign clinical course. In our case, only a slight expression 
of CD99 was observed both in primary and in-transit metastatic lesions. In other words, 
the lack of CD99 expression in our case may have been the cause of the in-transit 
metastasis of the primary tumor. 
Regarding treatment, initial wide excision is recommended because of the tendency for 
local recurrences, which generally increases the risk of metastasis. In the present case, no 
recurrence occurred over a period of 5 years; however, there was in-transit metastasis 
together with a history of local recurrence.  
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Fig. 1. A skin-colored, well-demarcated tumor located on the left side of the occipital region. 
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Fig. 2. The biopsy specimen revealed a significant number of minimal atypical spindle or stellate cells in 
the middle to deep dermis (a). Immunohistochemical staining of the biopsy specimens revealed that the 
tumor was mainly factor XIIIa positive (b), and CD34 negative (c). a: HE stain, ×10; b: factor XIIIa, 
×200; c: CD34 stain, ×200. 
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Fig. 3. The main bulk of the primary tumor was located from the dermis to the subcutaneous tissue (a). 
In the primary tumor, the dermal lesion consisted of scattered, minimal atypical spindle or stellate cells 
and foam cells with myxoid matrices (b, c). Immunohistochemical staining of the primary tumor 
revealed that the tumor was only slightly CD99 positive (d). In-transit metastasis: the tumor was 
composed of densely proliferating spindle cells with moderate pleomorphism arranged in a haphazard 
fashion (e). In-transit metastasis: the main tumor was located in the subcutaneous tissue, though, the 
overlying dermis showed no signs of the tumor (f). HE stain. a: ×5; b: ×200; c: ×100; d: CD99 stain. 
×400; e: ×400; f: ×50; original magnification. 
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